DJIA 17,721.65 91.38 0.52%
NASDAQ 5,093.89 4.68 0.09%
S&P 500 2,104.83 11.58 0.55%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

Daily Dividend Report: AAPL, MRK, JCI, ZTS, NTRS, FIS, MTB, AA, TXT

BRIEF-European Commission approves MSD's Keytruda for treatment of melanoma in adults

European Commission Approves MSD's Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line

European Commission Approves MSD's Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma

Will Agenus (AGEN) Disappoint Investors this Earnings? - Analyst Blog

A Few Key Points I Am Watching For From Gilead Sciences

Bristol-Myers Squibb Earnings: Did Opdivo & Elqiuis Sales Could Positively Impact Margins?

Bristol-Myers Squibb Earnings: Did Opdivo & Elqiuis Sales Could Positively Impact Margins?

Roche Earnings Are Likely To Show Resistance Against Competition

One Put, One Call Option To Know About for Merck & Co.

It's Not Too Late To Buy Gilead Sciences

Noteworthy ETF Inflows: VHT, PFE, MRK, MCK

See More Articles...